721 research outputs found
Trial brief, File no. 45738
No full textTrial brief in the case United States of America vs. Gordon Kiyoshi Hirabayashi, submitted by Hirabayashi's attorney Frank L. Walters in the northern division of the United States District Court for the Western District of Washington.The ACLU-Northern California case file records contain legal documents and correspondence pertaining to the case Ex parte Mitsuye Endo (1944), in which the United States Supreme court unanimously ruled that the federal government could not indefinitely detain United States citizens who were loyal to the government. Files include documents related to the Gordon Hirabayashi Supreme Court case Hirabayashi v. United States
Letter from Ernest Besig, Director, American Civil Liberties Union of Northern California, to Frank L. Walters, Esq., September 10, 1942
No full textLetter from Ernest Besig to Frank L. Walters, stating that Judge Welsh had not yet filed an opinion in the Korematsu case. Besig provides overview of Korematsu's status as a Unites States citizen, and writes: "Mr. Collins and I went to Tanforan Assembly Center and had Korematsu sign the Notice of Appeal, and also an affidavit to support an order to allow the appellant to prosecute the appeal in forma pauperis."The ACLU-Northern California case file records contain legal documents and correspondence pertaining to the case argued before the Supreme Court in Korematsu v. United States (1944), challenging the constitutionality of Executive Order 9066
Letter from Ernest Besig, Director, American Civil Liberties Union of Northern California, to Frank L. Walters, July 1, 1942
No full textLetter from Ernest Besig to Frank L. Walters, inquiring about the status of a case - possibly that of Gordon Hirabayashi. Besig mentions a "change of policy on the part of the New York office" with regard to representing Japanese Americans resisting forced removal and incarceration, and states ACLU of Northern California's intention to go ahead with the Korematsu case.The ACLU-Northern California case file records contain legal documents and correspondence pertaining to the case argued before the Supreme Court in Korematsu v. United States (1944), challenging the constitutionality of Executive Order 9066
L-R: Katie Lee; Natalie Gignoux; Leo Walters exploring a side canyon.
No full textPhoto of Arizona folk singer and author Katie Lee (far left), Natalie Gignoux (center), and Leo Walters (far right) exploring a side canyon in Glen Canyon, Uta
L-R: Katie Lee; Leo Walters; Bruce Berger sitting on a boat on the Colorado River.
No full textPhoto of Photo of Arizona folk singer and author Katie Lee (far left), Leo Walters (center), and writer Bruce Berger (far right), sitting on a raft on the Colorado River, Glen Canyon, Uta
L-R: Katie Lee (in boat); Leo Walters; Natalie Gignoux loading rafts with gear during their trip down Glen Canyon.
No full textPhoto of Arizona folk singer and author Katie Lee (sitting in raft), Leo Walters (standing next to raft), and Natalie Gignoux (far right), next to the Colorado River, Glen Canyon, Uta
CT angiography with cardiac MRI: Non-invasive functional and anatomical assessment for the etiology in newly diagnosed heart failure
No full textExclusion of ischemia is important in patients with newly diagnosed systolic heart failure (HF). We prospectively compared standard-of-care invasive catheter angiography (iCA) and echocardiography to a novel non-invasive strategy of both Coronary Computed Tomographic Angiography (CCTA) and Cardiovascular MRI (CMR) to determine the etiology of myocardial dysfunction Prospective data were collected from consecutive patients referred for iCA to investigate echocardiographically-confirmed new onset HF. CMR (1.5T GE) and dual source CCTA were performed within 2-7 days of iCA. Results were blinded and separately analyzed by expert readers. 426 coronary segments from 28 prospectively enrolled patients were analyzed by CCTA and quantitative iCA. The per-patient sensitivity and specificity of CCTA was 100% and 90%, respectively, negative predictive value (NPV) 100%, positive predictive value (PPV) 78%. Mean ejection fraction by CMR was 24%. Presence of ischemic-type LGE on CMR conferred a 67% sensitivity, 100% specificity, 90% NPV and 100% PPV. Combining CCTA with CMR conferred 100% specificity, 100% sensitivity, 100% PPV and 100% NPV for detection or exclusion of coronary disease. In patients with negative CCTA all invasive angiograms could have been avoided. In addition, two patients with no ischemic LGE by CMR had severe coronary disease on both CCTA and iCA, indicating global hibernation. This is a noteworthy finding in contrast to previous reports which suggested that absence of LGE rules out significant CAD. CCTA with CMR in newly-diagnosed HF enables non-invasive assessment of coronary artery disease, the severity and etiology of myocardial dysfunction and defines suitability for revascularization. Absence of ischemic-type LGE at CMR does not exclude CAD as a cause of LV dysfunction. A first-line strategy of functional and anatomic imaging with CMR and CCTA appears appropriate in newly diagnosed HF
Letter from Roger Baldwin, Director, American Civil Liberties Union, to Homer L. Morris, American Friends Service Committee, March 1, 1943
No full textLetter from Roger Baldwin to Homer L. Morris, regarding funds being raised by the American Friends Service Committee to support attorney Frank L. Walters argument of Gordon Hirabayashi's case in the Supreme Court. Baldwin quotes Joseph Conard's letter (chs_ms3580_0196) warning of Walters' poor performance representing Hirabayashi in the Circuit Court of Appeals at San Francisco. Baldwin writes: "I should think it would be wise now, in the event of an adverse decision which is expected, to see that somebody else than Mr. Walters argues the case in the Supreme Court. We should be very glad to make recommendations if you wish."The ACLU-Northern California case file records contain legal documents and correspondence pertaining to the case Ex parte Mitsuye Endo (1944), in which the United States Supreme court unanimously ruled that the federal government could not indefinitely detain United States citizens who were loyal to the government. Files include documents related to the Gordon Hirabayashi Supreme Court case Hirabayashi v. United States
Current asthma contributes as much as smoking to chronic bronchitis in middle age: a prospective population-based study [Corrigendum]
No full textDharmage SC, Perret JL, Burgess JA, et al. Int J Chron Obstruct Pulmon Dis. 2016;11:1911–1920. On page 1911, the author list “Shyamali C Dharmage,1 Jennifer L Perret,1,2 John A Burgess,1 Caroline J Lodge,1 David P Johns,3 Paul S Thomas,4 Graham G Giles,1,5 John L Hopper,1,6 Michael J Abramson,7,8 E Haydn Walters,3,9 Melanie C Matheson1” should have read “Shyamali C Dharmage,1,* Jennifer L Perret,1,2,* John A Burgess,1 Caroline J Lodge,1 David P Johns,3 Paul S Thomas,4 Graham G Giles,1,5 John L Hopper,1,6 Michael J Abramson,7,8 E Haydn Walters,3,9 Melanie C Matheson1”, and was missing the following statement “*These authors contributed equally to this work”.Read the original articl
Clinical and angiographic results with the next-generation resolute stent system A prospective, multicenter, first-in-human trial
No full textObjectivesThe RESOLUTE trial examined the safety and efficacy of a next-generation zotarolimus-eluting coronary stent, Resolute (Medtronic CardioVascular Inc., Santa Rosa, California).BackgroundRevascularization benefits associated with current drug-eluting stents are often diminished in the presence of complex coronary lesions and in certain patient cohorts. Resolute uses a new proprietary polymer coating that extends the duration of drug delivery to match the longer healing duration often experienced in more complex cases.MethodsThe RESOLUTE trial was a prospective, nonrandomized, multicenter study of the Resolute stent in 139 patients with de novo coronary lesions with reference vessel diameters > or =2.5 and or =14 and ResultsThe 9-month in-stent late lumen loss was 0.22 +/- 0.27 mm. Cumulative MACE were 4.3%, 4.3%, 7.2%, and 8.7% at 30 days, 6, 9, and 12 months, respectively. Acute lesion, procedure, and device success rates were 100.0%, 95.7%, and 99.3%, respectively. At 9 months, TLR was 0.0%, TVF was 6.5%, stent thrombosis was 0.0%, NIH volume was 6.55 +/- 7.83 mm(3), and percent NIH volume obstruction was 3.73 +/- 4.05%.ConclusionsIn this feasibility study, the Resolute stent demonstrated low in-stent late lumen loss, minimal neointimal hyperplastic ingrowth, low TLR, no stent thrombosis, and acceptable TVF and MACE. (The RESOLUTE Clinical Trial; NCT00248079).Ian T. Meredith, Stephen Worthley, Robert Whitbourn, Darren L. Walters, Dougal McClean, Mark Horrigan, Jeffrey J. Popma, Donald E. Cutlip, Ann DePaoli, Manuela Negoita, Peter J. Fitzgerald, for the RESOLUTE Investigator
- …
